Digital Therapeutics Commercialization Playbook: Reimbursement Risk Mapping.

Digital therapeutics face evolving reimbursement landscapes in the US, Europe, and Asia-Pacific, driven by high-quality evidence and payer collaboration. Germany's DiGA pathway has seen 374,000 prescriptions by September 2023, illustrating potential revenue impact. Temporary models in South Korea offer early adoption but hinge on post-coverage evaluation.Global trends indicate a shift toward outcome-based reimbursement and accelerated access models, as seen in Medicare’s digital mental health payments starting 2025. Successful integration into care ecosystems and robust real-world evidence collection are pivotal for long-term sustainability. Investors should focus on scalable strategies and adaptable policies.